#USA #Philadelphia #CEO Appointment #Minaris Advanced #Orla Cloak

Minaris Advanced Therapies Welcomes New Leadership

Minaris Advanced Therapies, a leading organization in cell and gene therapy contract development and manufacturing, is thrilled to announce the appointment of Dr. Orla Cloak as its Chief Executive Officer. With an impressive career spanning more than two decades in the pharmaceutical and life sciences sectors, Dr. Cloak brings a wealth of knowledge and strategic expertise to the role.

A Leader of Distinction

Dr. Cloak's experience includes significant leadership positions at Lonza, a global leader in biopharmaceuticals, where she spent 17 years. Most recently, she served as Senior Vice President and Head of the Lonza Bioscience Business Segment, further solidifying her reputation in the industry. Her academic qualifications, including a Bachelor of Science degree from University College Dublin and a PhD in Microbiology from the University of Ulster, underline her technical and scientific credentials.

The Chairman of Minaris, Iain Baird, expressed enthusiasm about Dr. Cloak’s appointment. "On behalf of the board, I am pleased to welcome Orla to Minaris Advanced Therapies. Her leadership will be pivotal in achieving our mission to support clients in successfully commercializing their innovative therapies," said Baird, highlighting the trust placed in her capabilities to navigate the complexities of the healthcare landscape.

Vision for the Future

In her statement, Dr. Cloak shared her excitement about joining the team at a critical juncture. She emphasized her enthusiasm for collaborating with the talented workforce at Minaris to build on the company's solid foundation and foster its next growth phase. Under her guidance, the organization aims to enhance its innovative capabilities, operational excellence, and sustainable business growth.

Minaris Advanced Therapies operates a global network that supports therapy developers from initial development through clinical trials to commercial manufacturing, boasting over 650,000 square feet of infrastructure across the U.S., Europe, and Asia. With more than 7,500 batches produced in compliance with Good Manufacturing Practices (GMP), Minaris is a trusted partner for therapeutic developers worldwide.

Their commitment is reflected through their specialized services in both cell and gene therapy, emphasizing the importance of innovation in creating impactful medical solutions. Dr. Cloak’s leadership will likely bring a renewed focus on advancing the company’s capabilities in these fields, driving continued success and transforming the way therapies are developed and brought to market.

A Strong Backing

Minaris Advanced Therapies is part of Altaris, an investment firm dedicated to acquiring and developing healthcare companies. Since its inception in 2003, Altaris has made significant investments in numerous health subsectors, maintaining a focus on creating value for the healthcare system while delivering attractive financial returns for investors. With Altaris as a backing partner, Minaris is in a robust position to capitalize on growth opportunities and invest in the future of healthcare.

The appointment of Dr. Orla Cloak comes at a pivotal time for Minaris Advanced Therapies, as the healthcare landscape continues to evolve rapidly, demanding leaders who are not only experienced but possess a visionary approach to innovation and strategic management.

As she steps into her new role, there is a collective anticipation that Dr. Cloak will lead the company into a new era of growth and excellence, supporting the advancement of groundbreaking therapies that have the potential to change patients’ lives.

For more information about Minaris Advanced Therapies, visit their official website at www.minaris.com.